COMPARISON OF ANALYSIS APPROACHES FOR PHASE III CLINICAL TRIALS IN AMYOTROPHIC LATERAL SCLEROSIS

被引:20
|
作者
Healy, Brian C. [1 ,2 ]
Schoenfeld, David [1 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[2] Brigham & Womens Hosp, Partners MS Ctr, Brookline, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
amyotrophic lateral sclerosis; clinical trial; longitudinal analysis; sample size calculations; survival analysis; PLACEBO-CONTROLLED TRIAL; FUNCTIONAL RATING-SCALE; LONGITUDINAL DATA; ALS; MODELS; MULTICENTER;
D O I
10.1002/mus.23392
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores. Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated. Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality. Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches. Muscle Nerve 46: 506-511, 2012
引用
收藏
页码:506 / 511
页数:6
相关论文
共 50 条
  • [1] Clinical trials in amyotrophic lateral sclerosis
    McDermott, Christopher J.
    CURRENT OPINION IN NEUROLOGY, 2019, 32 (05) : 758 - 763
  • [2] Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials
    Balendra, Rubika
    Jones, Ashley
    Jivraj, Naheed
    Steen, I. Nick
    Young, Carolyn A.
    Shaw, Pamela J.
    Turner, Martin R.
    Leigh, P. Nigel
    Al-Chalabi, Ammar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (01): : 45 - 49
  • [3] Designing Clinical Trials in Amyotrophic Lateral Sclerosis
    Shefner, Jeremy M.
    PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2008, 19 (03) : 495 - +
  • [4] Current clinical trials in amyotrophic lateral sclerosis
    Bhatt, Jaydeep M.
    Gordon, Paul H.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (08) : 1197 - 1207
  • [5] Advances in clinical trials for amyotrophic lateral sclerosis
    Gordon P.H.
    Current Neurology and Neuroscience Reports, 2005, 5 (1) : 48 - 54
  • [6] Comparison of Demographics: National Amyotrophic Lateral Sclerosis Registry and Clinical Trials Data
    Han, Moon
    Raymond, Jaime
    Larson, Theodore C.
    Mehta, Paul
    Horton, D. Kevin
    JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2024,
  • [7] Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
    Meininger, V
    Bensimon, G
    Bradley, WG
    Brooks, BR
    Douillet, P
    Eisen, AA
    Lacomblez, L
    Leigh, PN
    Robberecht, W
    AMYOTROPHIC LATERAL SCLEROSIS, 2004, 5 (02): : 107 - 117
  • [8] Sequential designs for clinical trials in amyotrophic lateral sclerosis
    Groeneveld, GJ
    van der Tweel, I
    Wokke, JHJ
    van den Berg, LH
    AMYOTROPHIC LATERAL SCLEROSIS, 2004, 5 (04): : 202 - 207
  • [9] Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
    Goyal, Namita A.
    Berry, James D.
    Windebank, Anthony
    Staff, Nathan P.
    Maragakis, Nicholas J.
    van den Berg, Leonard H.
    Genge, Angela
    Miller, Robert
    Baloh, Robert H.
    Kern, Ralph
    Gothelf, Yael
    Lebovits, Chaim
    Cudkowicz, Merit
    MUSCLE & NERVE, 2020, 62 (02) : 156 - 166
  • [10] Xaliproden in amyotrophic lateral sclerosis: early clinical trials
    Lacomblez, L
    Bensimon, G
    Douillet, P
    Doppler, V
    Salachas, F
    Meininger, V
    AMYOTROPHIC LATERAL SCLEROSIS, 2004, 5 (02): : 99 - 106